Leuprolide acetate receives FDA new drug application
Links shared publicly online about this topic.
- 0total visits
Leuprolide acetate receives FDA new drug application
View full resource at pediatricsupersite.com
Tags: Prostate Cancer Medication, Drug, FDA, Lupron, Leuplin
Most Recently Shared on October 28, 2011 at 1:01 pm By:
Leuprolide acetate receives FDA new drug application http://t.co/ZYs4ZXIF
Leuprolide acetate receives FDA new drug application - DoctorsHangout.com
doctorshangout.com — “The FDA has approved a new drug application for leuprolide acetate for depot suspension, a 1-month formulation for the treatment of central precocious puberty.…” View full resource at doctorshangout.com
Most Recently Shared on December 21, 2011 at 6:08 pm By:
Leuprolide acetate receives FDA new drug application: The FDA has approved a new drug application for leuprolide... http://t.co/Eerwp5Vp
Lupron Depot-PED Labeling Updated to Include 18 Year Data - MPR
empr.com — “Abbott announced that the FDA has approved a supplemental New Drug Application (NDA) for Lupron Depot-PED (leuprolide acetate for depot suspension).” View full resource at empr.com
Most Recently Shared on October 28, 2011 at 1:23 pm By:
Lupron Depot-PED Labeling Now Includes Long-Term Data http://t.co/dR6CVHMQ #endocrinology
Leuprolide acetate receives FDA new drug application
endocrinetoday.com — “The FDA has approved a new drug application for leuprolide acetate for depot suspension, a 1-month formulation for the treatment of central precoci” View full resource at endocrinetoday.com
Most Recently Shared on October 27, 2011 at 9:56 pm By:
Leuprolide acetate receives #FDA new drug application http://t.co/9X93nlrq
Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA
news-medical.net — “Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).” View full resource at news-medical.net
Most Recently Shared on December 24, 2010 at 9:29 am By:
Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA: Teva Pharmaceutical Indu... http://bit.ly/igICC8
Abbott Seeks FDA Approval for Six-Month Lupron Depot - Renal and Urology News
renalandurologynews.com — “The FDA is reviewing Abbott's supplemental New Drug Application for a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer.” View full resource at renalandurologynews.com
Most Recently Shared on April 27, 2010 at 7:02 pm By:
Renal Urology News Nephrology, Urology, Medical Publisher, and Health News
Abbott Seeks FDA Approval for Six-Month Lupron Depot: The FDA is reviewing Abbott's supplemental New Drug Applicat... http://bit.ly/dtrOBt
Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review
news-medical.net — “The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.” View full resource at news-medical.net
Most Recently Shared on March 12, 2010 at 10:23 am By:
Prostate Cancer: Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review: The ... http://bit.ly/bNgN42
Sepracor's STEDESA NDA: FDA extends PDUFA action date
news-medical.net — “Sepracor Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency now anticipates completing its review of the STEDESA" (eslicarbazepine acetate) New Drug Application (NDA) on April 30, 2010, which is a three-month extension to the original Prescription Drug User Fee Act (PDUFA) date of January 30, 2010.” View full resource at news-medical.net
Most Recently Shared on January 28, 2010 at 5:22 am By:
Sepracor's STEDESA NDA: FDA extends PDUFA action date: Sepracor Inc. today announced that it has received notifica... http://bit.ly/cTfCd3
Advertisement
